Drugs / LY4268989
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07707375 | Jul → Oct 2026 expected | — | Eli Lilly and Company | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06964776 | May 2025 → Feb 2026 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04580745 | Sep 2020 → Mar 2021 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT07415044 | Mar 2026 → Jun 2030 expected | ulcerative colitis | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 2 | NCT07186101 | Nov 2025 → May 2027 expected | ulcerative colitis | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 2 | NCT06226883 | Jul 2024 → Sep 2028 expected | Crohn disease | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 2 | NCT05611671 | Nov 2022 → Nov 2024 overdue | ulcerative colitis | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05291689 | Apr 2022 → Oct 2023 | ulcerative colitis | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY4268989 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06964776 ↗ |
| Known as | MORF-057 | “A Study of LY4268989 (MORF-057) in Healthy Participants” NCT06964776 ↗ |
| Known as | MORF-57 | “The purpose of this study is to measure the body's absorption and processing of the study drug, the study drug's effect on the body, safety, and tolerability with LY4268989...” NCT06964776 ↗ |
| Action | Inhibit | “designed to selectively inhibit integrin α4β7” NCT05291689 ↗ |
| Modality | Small molecule | “MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.” NCT05291689 ↗ |
| Route | Oral | “Oral MORF-057” NCT04580745 ↗ |